Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CytomX Therapeutics Inc CTMX

Healthcare Biotechnology
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic... see more

Recent & Breaking News (NDAQ:CTMX)

CytomX Announces Selection by Bristol-Myers Squibb of First Clinical Candidate Probody From Collaboration

GlobeNewswire December 13, 2016

CytomX Announces Fourth Target Selection by Bristol-Myers Squibb Under Strategic Oncology Collaboration

GlobeNewswire December 5, 2016

CytomX to Present at the Jefferies 2016 London Healthcare Conference

GlobeNewswire November 9, 2016

CytomX Therapeutics Announces Third Quarter 2016 Financial Results and Provides Pipeline Update

GlobeNewswire November 3, 2016

CytomX Therapeutics to Announce Third Quarter 2016 Financial Results

GlobeNewswire October 27, 2016

CytomX Announces Second Quarter 2016 Financial Results

GlobeNewswire August 3, 2016

CytomX Therapeutics to Announce Second Quarter 2016 Financial Results and Provide Mid-Year Update

GlobeNewswire July 27, 2016

CytomX Therapeutics Appoints John A. Scarlett, M.D., to Board of Directors

GlobeNewswire June 13, 2016